BH3 Peptides induces a decrease in mitochondrial membrane potential but does not engage the Permeability Transition Pore. by Emelyn H. Shroff (163459)

Compounds decrease polyQ toxicity in a <i>pqe-1</i> independent manner in aged animals. by Cindy Voisine (30589)

Effects of protein-bound uremic solutes on total glutathione level. by Takeo Edamatsu (4885138)

Pretreatment of β-cells with recombinant CXCL12 improves viability and induces a decrease in PARP-1 activity. by Nevena Grdović (394542)

Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC₅₀ concentration of fenretinide during different time points (24–48–72 hours). …”

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. Positive controls Cisplatin and doxorubicin against gastrointestinal and colorectal... by MohammedBashar Al-Qazzan (22439236)

Decreased Platelet Count in Patients Receiving Continuous Veno-Venous Hemofiltration: A Single-Center Retrospective Study by Buyun Wu (563610)

“…During the 3-day CVVH, 44.8% and 16% patients had a mild decline (20–49.9%) and severe decline (≥50%) in the platelet count,respectively; 37.6% and 16.0% patients had mild thrombocytopenia (platelet count 50.1–100×10⁹/L) and severe thrombocytopenia (platelet count ≤50×10⁹/L), respectively. …”

Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. by Mariam El-Ashmawy (678638)

“…Data analyzed and calculated using Open Comet software [tail moment = tail length x tail DNA percentage]. Mean ± SEM of >50 cells per condition, *p<0.05 using t-test (compared to 3 Gy DMSO). …”

Decreased IFNγ production by Ly49H⁺ NK cells in A/J mice. by Nassima Fodil (669326)

Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

“…<i>n</i> = 3 mice per genotype. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.001 versus Scrib WT CL. Scale bars: A,B,D,E: 2 μm. J,K: 50 μm.</p>…”

Living cells are decreased in the PDL on the pressure side of a Pn−/− molar tooth subjected to experimental tooth movement. by Hideyuki Tanabe (243557)

Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study by Ho D. (4108837)

“…<p><b><i>Objectives:</i></b> To determine whether there are any fetal cardiac function changes, as measured by the myocardial performance index (MPI), in pregnancies complicated by decreased fetal movement (DFM). <b><i>Methods:</i></b> We performed a prospective cross-sectional case-control study of 50 DFM and 50 uncomplicated third-trimester pregnancies matched within 2 gestational weeks. …”

S10 Data - by Christoph Anders (4068499)

“…<div><p>Hysteresis refers to a physical phenomenon in which the response or state of a system depends on both the input variable and its history. …”

WNF decreases Aβ peptides generation in HEK293 and SH-SY5Y human cells. by Htut Htut Htoo (3686641)

Decreased CCL2 levels protect A20^AEC-KO mice against influenza A infection by Jonathan Maelfait (181048)

E₅₀ values. by Junxia Zhou (14381598)

Tempol and L-NAME help prevent the decrease in F_max. by Travis L. Dutka (321984)

Terpenoids decrease single-channel activity of L-AChRs elicited by ACh. by Guillermina Hernando (553795)

Drugs which cluster on the 'anxiolytic' group decrease 5-HT turnover in the brain. by Caio Maximino (100467)

“…Points represent means and error bars represent standard errors. A negative correlation is found between the decrease in serotonin turnover and the increase in time on white produced by a drug (r² = 0.5688, p = 0.0073).…”

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”